YD Bio Limited Ordinary Shares(YDES)Earnings, Financials & Key Ratios
YDES•NASDAQ
$5.19
$22M mkt cap·Price updated May 6, 2026
AboutBreeze Holdings Acquisition Corp. operates as a clinical-stage biopharmaceutical company focuses on cancer prevention medical diagnostics and the development of exosome-based therapeutics with the potential to transform the treatment of a diseases with unmet medical need. The company is based in Taipei, Taiwan.Show more
- Revenue$510K+45.8%
- EBITDA-$1M-18252.9%
- Net Income-$1M-10509.7%
- EPS (Diluted)-0.56-280100.0%
- Gross Margin30.44%-30.5%
- EBITDA Margin-265.93%-12490.7%
- Operating Margin-286.45%-10085.3%
- Net Margin-276.58%-7241.6%
- ROE-42.69%-17761.9%
- ROIC-63.31%-47750.1%
- Debt/Equity0.00-99.8%
- Interest Coverage-1893.69-41131.6%
YDES Key Insights
YD Bio Limited Ordinary Shares (YDES) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓High quality earnings: Operating CF exceeds net income
- ✓Share count reduced 94.1% through buybacks
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 4 (bottom 4%)
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
YDES Price & Volume
YD Bio Limited Ordinary Shares (YDES) stock price & volume — 10-year historical chart
Loading chart...
YDES Growth Metrics
YD Bio Limited Ordinary Shares (YDES) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-
Return on Capital
10 Years-9.94%
5 Years-9.94%
3 Years-15.97%
Last Year-44.14%
YDES Peer Comparison
YD Bio Limited Ordinary Shares (YDES) competitors in Diagnostics and Omics Tools — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 BTBT | 621.7M | 1.93 | 9.65 | 264.59% | 21.41% | 0.03 | ||
 NUVB | 1.75B | 5.04 | -8.40 | 6.99% | -102.06% | -44.1% | 0.03 | |
 ZLAB | 2.32B | 21.01 | -13.13 | 15.33% | -38.15% | -22.81% | 0.31 | |
 ZYME | 2.05B | 27.61 | -25.56 | 38.87% | -76.56% | -26% | 0.07 | |
 IQ | 1.19B | 1.23 | 10.89 | -8.31% | -1.44% | -2.92% | 1.06 | |
 TIGR | 676.45M | 6.93 | 19.25 | 43.68% | 17.64% | 0.27 | ||
 LEGN | 5.35B | 28.96 | -8.99 | 64.47% | -28.83% | -29.22% | 0.41 | |
 CGEN | 247.13M | 2.76 | -17.25 | -16.72% | -5.77% | -71.54% | 0.05 |
Compare YDES vs Peers
YD Bio Limited Ordinary Shares (YDES) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
YDES Income Statement
YD Bio Limited Ordinary Shares (YDES) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 350.13K | 510.36K | 0 |
| Revenue Growth % | - | - | - | - | 45.76% | - |
| Cost of Goods Sold | 0 | 0 | 0 | 196.69K | 355K | 0 |
| COGS % of Revenue | - | - | - | 56.17% | 69.56% | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 153.44K▲ 0% | 155.36K▲ 1.2% | 0▲ 0% |
| Gross Margin % | - | - | - | 43.82% | 30.44% | - |
| Gross Profit Growth % | - | - | - | - | 1.25% | - |
| Operating Expenses | 344.22K | 1.72M | 2.32M | 163.29K | 1.62M | 1.38M |
| OpEx % of Revenue | - | - | - | 46.64% | 316.89% | - |
| Selling, General & Admin | 344.22K | 1.72M | 2.32M | 160.56K | 1.13M | 1.38M |
| SG&A % of Revenue | - | - | - | 45.86% | 220.71% | - |
| Research & Development | 0 | 0 | 0 | 0 | 491.35K | 0 |
| R&D % of Revenue | - | - | - | - | 96.28% | - |
| Other Operating Expenses | 0 | 0 | 0 | 2.73K | -493 | 0 |
| Operating Income | -344.22K▲ 0% | -1.72M▼ 400.4% | -2.32M▼ 34.9% | -9.85K▲ 99.6% | -1.46M▼ 14746.5% | -1.38M▲ 0% |
| Operating Margin % | - | - | - | -2.81% | -286.45% | - |
| Operating Income Growth % | - | -400.36% | -34.88% | 99.58% | -14746.45% | - |
| EBITDA | -2.54M | 8.7M | 3.79M | -7.39K | -1.36M | -2.99M |
| EBITDA Margin % | - | - | - | -2.11% | -265.93% | - |
| EBITDA Growth % | - | 442.99% | -56.45% | -100.2% | -18252.87% | - |
| D&A (Non-Cash Add-back) | 0 | 0 | 0 | 2.45K | 104.73K | 0 |
| EBIT | -2.54M | 8.7M | 3.79M | 19.79K | -1.39M | -2.99M |
| Net Interest Income | 178 | 764 | 813 | -1.85K | 11.04K | 326.75K |
| Interest Income | 178 | 764 | 813 | 290 | 11.81K | 326.75K |
| Interest Expense | 0 | 0 | 0 | 2.14K | 772 | 0 |
| Other Income/Expense | -2.19M | 10.43M | 6.11M | 27.5K | 75.45K | -1.6M |
| Pretax Income | -2.54M▲ 0% | 8.7M▲ 443.0% | 3.79M▼ 56.5% | 17.65K▼ 99.5% | -1.39M▼ 7955.4% | -2.99M▲ 0% |
| Pretax Margin % | - | - | - | 5.04% | -271.67% | - |
| Income Tax | 0 | 0 | 2.09K | 4.09K | 25.08K | -11.97K |
| Effective Tax Rate % | 0% | 0% | 0.06% | 23.17% | -1.81% | 0.4% |
| Net Income | -2.54M▲ 0% | 8.7M▲ 443.0% | 3.79M▼ 56.5% | 13.56K▼ 99.6% | -1.41M▼ 10509.7% | -2.97M▲ 0% |
| Net Margin % | - | - | - | 3.87% | -276.58% | - |
| Net Income Growth % | - | 442.99% | -56.48% | -99.64% | -10509.73% | - |
| Net Income (Continuing) | -2.54M | 8.7M | 3.79M | 13.56K | -1.41M | -2.97M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.17▲ 0% | 0.59▲ 447.1% | 0.41▼ 30.5% | 0.00▼ 100.0% | -0.56▼ 280100.0% | -0.87▲ 0% |
| EPS Growth % | - | 447.06% | -30.51% | -99.95% | - | - |
| EPS (Basic) | -0.17 | 0.59 | 0.41 | 0.00 | -0.56 | - |
| Diluted Shares Outstanding | 14.63M | 14.63M | 9.29M | 70.1M | 4.15M | 3.41M |
| Basic Shares Outstanding | 14.63M | 14.63M | 9.29M | 70.1M | 4.15M | 3.41M |
| Dividend Payout Ratio | - | - | - | - | - | - |
YDES Balance Sheet
YD Bio Limited Ordinary Shares (YDES) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Total Current Assets | 830.77K | 129.56K | 202.71K | 271.72K | 3.47M | 192.08K |
| Cash & Short-Term Investments | 693.82K | 5.4K | 14.13K | 87.1K | 3.13M | 6.31K |
| Cash Only | 693.82K | 5.4K | 14.13K | 87.1K | 3.13M | 6.31K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 18.07K | 98.43K | 262.8K | 53.91K |
| Days Sales Outstanding | - | - | - | 102.61 | 187.95 | - |
| Inventory | 0 | 0 | 0 | 69.4K | 37.34K | 0 |
| Days Inventory Outstanding | - | - | - | 128.8 | 38.39 | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 116.76M | 117.93M | 17.73M | 49.49K | 3.4M | 2.76M |
| Property, Plant & Equipment | 0 | 0 | 0 | 14.3K | 88.08K | 0 |
| Fixed Asset Turnover | - | - | - | 24.48x | 5.79x | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 2.68M | 0 |
| Long-Term Investments | 116.73M | 117.93M | 17.73M | 10.62K | 10.53M | 27.15M |
| Other Non-Current Assets | 23.29K | 0 | 0 | 0 | -9.9M | -9.9M |
| Total Assets | 117.59M▲ 0% | 118.06M▲ 0.4% | 17.93M▼ 84.8% | 321.21K▼ 98.2% | 6.86M▲ 2037.0% | 2.95M▲ 0% |
| Asset Turnover | - | - | - | 1.09x | 0.07x | 0.00x |
| Asset Growth % | - | 0.4% | -84.81% | -98.21% | 2036.98% | -194.53% |
| Total Current Liabilities | 302.22K | 2M | 5.55M | 298.22K | 263.06K | 11.22M |
| Accounts Payable | 0 | 0 | 0 | 17.98K | 26.74K | 0 |
| Days Payables Outstanding | - | - | - | 33.36 | 27.5 | - |
| Short-Term Debt | 0 | 0 | 0 | 34.32K | 290 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 302.22K | 2M | 5.55M | 344 | 0 | 11.15M |
| Current Ratio | 2.75x | 0.06x | 0.04x | 0.91x | 13.18x | 13.18x |
| Quick Ratio | 2.75x | 0.06x | 0.04x | 0.68x | 13.04x | 13.04x |
| Cash Conversion Cycle | - | - | - | 198.05 | 198.84 | - |
| Total Non-Current Liabilities | 17.51M | 7.11M | 1.18M | 2.2M | 10.92K | 7.79M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 5.68K | 5.68K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 1.46K | 1.46K |
| Other Non-Current Liabilities | 17.51M | 7.11M | 1.18M | 2.2M | 3.77K | 17.27M |
| Total Liabilities | 17.81M | 9.11M | 6.74M | 298.22K | 273.98K | 19M |
| Total Debt | 0 | 0 | 0 | 47.58K | 22.55K | 0 |
| Net Debt | -693.82K | -5.4K | -14.13K | -39.52K | -3.11M | -6.31K |
| Debt / Equity | - | - | - | 2.07x | 0.00x | 0.00x |
| Debt / EBITDA | - | - | - | - | - | -0.00x |
| Net Debt / EBITDA | - | -0.00x | -0.00x | - | - | 0.00x |
| Interest Coverage | - | - | - | -4.59x | -1893.69x | - |
| Total Equity | 99.78M▲ 0% | 108.96M▲ 9.2% | 11.2M▼ 89.7% | 22.99K▼ 99.8% | 6.59M▲ 28560.7% | -16.05M▲ 0% |
| Equity Growth % | - | 9.2% | -89.72% | -99.79% | 28560.72% | -64.62% |
| Book Value per Share | 6.82 | 7.45 | 1.20 | 0.00 | 1.59 | -4.71 |
| Total Shareholders' Equity | 99.78M | 108.96M | 11.2M | 22.99K | 6.59M | -16.05M |
| Common Stock | 115M | 115M | 17.73M | 105.2K | 144.18K | 2.66M |
| Retained Earnings | -15.22M | -6.52M | -6.53M | -515.48K | -1.93M | -18.71M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 47.21K | 45.07K | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
YDES Cash Flow Statement
YD Bio Limited Ordinary Shares (YDES) cash flow — operating, investing & free cash flow history
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Cash from Operations | -253.63K | -688.41K | -3.02M | -55.66K | -1.84M | -1.84M |
| Operating CF Margin % | - | - | - | -15.9% | -359.91% | - |
| Operating CF Growth % | - | -171.43% | -339.09% | 98.16% | -3200.25% | 118.69% |
| Net Income | -2.54M | 8.7M | 3.79M | 13.56K | -1.41M | -2.97M |
| Depreciation & Amortization | 0 | 0 | 0 | 2.45K | 104.73K | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 4.09K | 26.58K | 0 |
| Other Non-Cash Items | 2.19M | -10.02M | -6.11M | 50.94K | 11.24K | 1.6M |
| Working Capital Changes | 90.42K | 632.18K | -697.49K | -126.7K | -567.81K | 196.36K |
| Change in Receivables | 0 | 0 | 0 | -63.86K | -11.02K | 0 |
| Change in Inventory | 0 | 0 | 0 | -30.57K | 28.52K | 0 |
| Change in Payables | 67.26K | 531.18K | -530.95K | 5.39K | 10.2K | 0 |
| Cash from Investing | -116.72M | -1.15M | 100.38M | -290 | -2.9M | 7.95M |
| Capital Expenditures | 0 | 0 | 0 | -290 | -74.91K | 0 |
| CapEx % of Revenue | - | - | - | 0.08% | 14.68% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 101.78M | 528.51K | -2.84M | 8.2M |
| Cash from Financing | 117.67M | 1.15M | -97.34M | 113.89K | 7.73M | -6.81M |
| Debt Issued (Net) | 0 | 1.15M | 4.2M | -32.61K | -32.98K | 1.13M |
| Equity Issued (Net) | 1000K | 0 | -1000K | 52.95K | 1000K | -1.58M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | -101.55M | 0 | 0 | -7.94M |
| Other Financing | 0 | 0 | 0 | 93.54K | -99.56K | 0 |
| Net Change in Cash | 693.82K▲ 0% | -688.41K▼ 199.2% | 8.73K▲ 101.3% | 56.96K▲ 552.7% | 3.05M▲ 5246.6% | -33.66K▲ 0% |
| Free Cash Flow | -253.62K▲ 0% | -688.42K▼ 171.4% | -3.02M▼ 339.1% | -55.95K▲ 98.1% | -4.75M▼ 8386.3% | -1.18M▲ 0% |
| FCF Margin % | - | - | - | -15.98% | -930.29% | - |
| FCF Growth % | - | -171.44% | -339.08% | 98.15% | -8386.27% | - |
| FCF per Share | -0.02 | -0.05 | -0.33 | -0.00 | -1.15 | -1.15 |
| FCF Conversion (FCF/Net Income) | 0.10x | -0.08x | -0.80x | -4.10x | 1.30x | 0.40x |
| Interest Paid | 0 | 0 | 0 | 2.14K | 772 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
YDES Key Ratios
YD Bio Limited Ordinary Shares (YDES) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Return on Equity (ROE) | 8.34% | 6.31% | 0.24% | -42.69% | 46.53% |
| Return on Invested Capital (ROIC) | -1.24% | -2.9% | -0.13% | -63.31% | -63.31% |
| Gross Margin | - | - | 43.82% | 30.44% | - |
| Net Margin | - | - | 3.87% | -276.58% | - |
| Debt / Equity | - | - | 2.07x | 0.00x | 0.00x |
| Interest Coverage | - | - | -4.59x | -1893.69x | - |
| FCF Conversion | -0.08x | -0.80x | -4.10x | 1.30x | 0.40x |
| Revenue Growth | - | - | - | 45.76% | - |
YDES Frequently Asked Questions
YD Bio Limited Ordinary Shares (YDES) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
YD Bio Limited Ordinary Shares (YDES) reported $0.5M in revenue for fiscal year 2024.
YD Bio Limited Ordinary Shares (YDES) grew revenue by 45.8% over the past year. This is strong growth.
YD Bio Limited Ordinary Shares (YDES) reported a net loss of $3.0M for fiscal year 2024.
Dividend & Returns
YD Bio Limited Ordinary Shares (YDES) has a return on equity (ROE) of -42.7%. Negative ROE indicates the company is unprofitable.
YD Bio Limited Ordinary Shares (YDES) had negative free cash flow of $1.2M in fiscal year 2024, likely due to heavy capital investments.
Explore More YDES
YD Bio Limited Ordinary Shares (YDES) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates